September 13 is designated as National Celiac Disease Awareness Day with the intention of raising awareness for and education of the disease, which affects approximately one in 133 Americans, according to Beyond Celiac.
Celiac disease often goes undiagnosed or misdiagnosed, and the only existing treatment for the disease is a 100% gluten-free diet, according to Beyond Celiac.
To mark National Celiac Disease Awareness Day, Healio Internal Medicine compiled a list of the most popular news articles on recent advancements in celiac disease research.
USPSTF: Insufficient evidence for celiac disease screening
There is a lack of current evidence to determine the balance of benefits and harms of screening for celiac disease in all asymptomatic adults, adolescents and children, according to a report issued by the U.S. Preventive Services Task Force. Read More.
More Americans follow gluten-free diet despite stable rate of celiac disease
The prevalence of celiac disease in the United States has plateaued, but the number of people following gluten-free diets has increased, according to findings published in JAMA Internal Medicine. Read More.
Oats appear safe for patients with celiac disease
Adding oats to increase the nutritional value of a gluten-free diet does not appear to affect symptoms, histology, immunity or serologic features of patients with celiac disease, according to new research published in Gastroenterology. Read More.
Nexvax2 alters immune response to gluten in patients with celiac disease
Nexvax2, an investigational therapeutic vaccine designed to protect patients with celiac disease against the effects of gluten exposure, was safe and well tolerated, and demonstrated a modified immune response to gluten in two phase 1 randomized controlled trials. Read More.
AGA President: 7 new developments in celiac disease, wheat sensitivity
CHICAGO — At the AGA Presidential Plenary at Digestive Disease Week, newly appointed AGA President Sheila Crowe, MD, from University of California, San Diego, highlighted the latest developments in celiac disease and wheat sensitivity disorders. Read More.
, placebo similarly improve histology, symptoms in celiac disease
Latiglutenase did not improve histologic and symptomatic measures of disease activity in patients with symptomatic celiac disease compared with placebo in a phase 2 study. Read More.